Related Experiment Video

Updated: Jun 19, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Is normalising haemoglobin in patients with CKD harmful and if so, why?

T J Littlewood1

  • 1Department of Haematology, Cancer and Haematology Centre, Churchill Hospital, Old Rd, Oxford OX37LJ, UK. tim.littlewood@chch.ox.ac.uk

Journal of Renal Care
|November 7, 2009
PubMed

Insights

Anemia treatment in chronic kidney disease (CKD) patients using erythropoiesis-stimulating agents (ESAs) may increase cardiovascular mortality if hemoglobin exceeds 13.0 g/dL. The exact cause for this heightened risk remains unclear.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Symptomatic anemia is a common complication in patients with chronic kidney disease (CKD).
  • Erythropoiesis-stimulating agents (ESAs) are frequently used to correct anemia in CKD patients, improving quality of life and life expectancy.
  • Previous understanding suggested benefits of anemia correction without clear upper limits for hemoglobin concentration.

Purpose of the Study:

  • To investigate the impact of hemoglobin concentration targets on cardiovascular disease (CVD) mortality in patients with chronic kidney disease (CKD).
  • To analyze data from both dialysis-dependent and non-dialysis-dependent CKD populations.

Main Methods:

  • Retrospective analysis of patient data from dialysis-dependent and non-dialysis-dependent CKD cohorts.
  • Comparison of cardiovascular disease mortality rates across different hemoglobin concentration levels.

Main Results:

  • Data indicate an increased risk of mortality from cardiovascular disease (CVD) when hemoglobin concentration is corrected above 13.0 g/dL in CKD patients.
  • This finding applies to both dialysis-dependent and non-dialysis-dependent patient groups.

Conclusions:

  • Current anemia management strategies in CKD patients require re-evaluation regarding target hemoglobin levels.
  • Achieving hemoglobin concentrations above 13.0 g/dL may be associated with increased cardiovascular mortality, necessitating further research into the underlying mechanisms.

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...